Form 4: Alaunos Therapeutics Director Boosts Shareholding

Alaunos Therapeutics Director Michael Allen Jerman acquired 5,406 shares of common stock at $2.89 per share, issued in lieu of board fees.

Summary

• Director Michael Allen Jerman of Alaunos Therapeutics, Inc. (TCRT) acquired 5,406 shares of common stock.
• The transaction occurred on January 12, 2026.
• The shares were acquired at a price of $2.89 per share.
• These shares were issued in lieu of board fees, as per the explanation of responses.
• Following this transaction, Mr. Jerman beneficially owns a total of 9,589 shares of common stock.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading plan.

Sentiment

Score: 6

Explanation: The acquisition of shares by a director, especially in lieu of cash fees, is generally viewed as a positive sign of confidence and alignment with shareholder interests, though the transaction size is relatively small and routine.

Positives

• Director Michael Allen Jerman increased his direct ownership in Alaunos Therapeutics by acquiring 5,406 shares.
• The acquisition of shares in lieu of cash fees demonstrates alignment of the director's interests with shareholders, signaling confidence in the company's future prospects.

Negatives

• No specific negative points are identified from this routine Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

This filing does not contain any forward-looking statements or guidance.

Industry Context

This is a routine insider transaction disclosure, common in the biotechnology or pharmaceutical industry (where Alaunos Therapeutics operates) for directors receiving equity as part of their compensation package. It reflects standard corporate governance practices regarding director remuneration.

Related Party Transactions

• Director Michael Allen Jerman, a related party, received 5,406 shares of common stock from Alaunos Therapeutics, Inc. in lieu of board fees.

Stakeholder Impact

• Shareholders: The transaction indicates a director's increased stake and alignment with shareholder interests, potentially signaling confidence in the company's future.
• Employees: No direct impact on employees is indicated.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Key Dates

Recommendation

This Form 4 filing reports a routine insider transaction where a director received shares in lieu of board fees. While it shows alignment of interests, the transaction size is not substantial enough to warrant a change in investment recommendation based solely on this disclosure. It's a neutral event for the stock's fundamental outlook.

Keywords

Alaunos Therapeutics, TCRT, Form 4, Insider Trading, Director Share Acquisition, Beneficial Ownership, Michael Allen Jerman, Equity Compensation